Buy Rating on Context Therapeutics's CTIM-76 Bolstered by Market Validation and Competitive Edge
Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics Advances Cancer Trial With FDA Submission
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a bio
Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Price Target Cut to $4.00/Share From $5.00 by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Lowers Price Target to $4
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics with a Buy and lowers the price target from $5 to $4.
Preston Fay Brings Data Analytics Leadership to The Context Network
WEST DES MOINES, Iowa, March 21, 2024 /PRNewswire/ -- Agribusiness consulting firm The Context Network (Context) is growing its data analytics practice, with Preston Fay joining the leadership team a
Context Therapeutics Reports FY Results
Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Context Therapeutics Reported FY23 EPS Loss of $(1.50) Vs $(0.93) YoY, Cash Balance of $14.4M
Press Release: Context Therapeutics Reports Full Year 2023 Operating and Financial Results
Context Therapeutics Reports Full Year 2023 Operating and Financial Results CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Compan
Context Therapeutics Unveils Updated Corporate Strategy Presentation
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAclarion (NASDAQ:ACON) stock rose 21.6% to $3.82 during Friday's after-market session. The company's market cap stands at $3.2 million. Outset Medical (NASDAQ:OM) shares rose 10.61% to $4.95. T
Constellation Energy, Battalion Oil And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Friday. Here are some other big stocks recording gains in today's session. Battalion Oil Corporation (NYSE:BATL) rose 8
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersExicure (NASDAQ:XCUR) stock increased by 63.9% to $0.66 during Friday's pre-market session. The market value of their outstanding shares is at $5.7 million. Atreca (NASDAQ:BCEL) shares rose 17.
Context Therapeutics' Promising Financial and Preclinical Results Bolster Buy Rating: A Focus on CTIM-76's High Potency and Target Specificity
Promising Potential of CTIM-76 Drug: A Comprehensive Buy Rating Analysis for Context Therapeutics
Context Therapeutics GAAP EPS of -$0.37 Misses by $0.06
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into lat
No Data